share_log

Clearmind Medicine | CORRESP: CORRESP

Clearmind Medicine | CORRESP: CORRESP

Clearmind Medicine | CORRESP：信函
SEC announcement ·  02/14 22:21
Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a biotechnology company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company aims for the Registration Statement to become effective on February 16, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. Clearmind Medicine has authorized its counsel, Greenberg Traurig, P.A., and specifically David Huberman, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.
Clearmind Medicine Inc., a biotechnology company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company aims for the Registration Statement to become effective on February 16, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. Clearmind Medicine has authorized its counsel, Greenberg Traurig, P.A., and specifically David Huberman, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.
生物技術公司Clearmind Medicine Inc. 已正式要求美國證券交易委員會（SEC）加快其F-1表格註冊聲明的生效。該公司的目標是使註冊聲明於美國東部時間2024年2月16日下午 4:00 生效。該請求是根據經修訂的1933年《證券法》第461條提出的。Clearmind Medicine已授權其法律顧問賓夕法尼亞州格林伯格·特勞裏格，特別是戴維·胡伯曼就註冊聲明的有效性與美國證券交易委員會進行溝通，並對加速請求進行任何必要的修改或撤回。
生物技術公司Clearmind Medicine Inc. 已正式要求美國證券交易委員會（SEC）加快其F-1表格註冊聲明的生效。該公司的目標是使註冊聲明於美國東部時間2024年2月16日下午 4:00 生效。該請求是根據經修訂的1933年《證券法》第461條提出的。Clearmind Medicine已授權其法律顧問賓夕法尼亞州格林伯格·特勞裏格，特別是戴維·胡伯曼就註冊聲明的有效性與美國證券交易委員會進行溝通，並對加速請求進行任何必要的修改或撤回。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息